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The health care professions have always enjoyed special trust
and position in our society. Patients trust health care
professionals (HCPs) to guard their health, inform them,
and put a patient’s interests above any other consideration.
This is one definition of “professionalism.” When HCPs
deal with human subjects in research there are basic ethical
principles, articulated in the classic Belmont Report of
1979, that have been accepted by all (1).
We believe from our experience that the members and
staff of the American College of Cardiology Foundation
(ACCF) and the American Heart Association (AHA) strive
to do “good” for society in general and for patients specif-
ically. They put patients’ interests first, above their own, in
an overwhelming majority of situations. There are virtually
hundreds of thousands of patient-HCP encounters daily in
the U.S. It is assumed that HCPs are trying their utmost to
benefit their patients even when the outcome is not optimal
or when disease progression cannot be effectively treated.
Complications of therapy occur despite the best of inten-
tions. Clinician-scientists and the medical industry develop
new therapies to improve the lives of patients living with
cardiovascular disease, and society has seen the benefits of
this effort over the past several years. Everything in this
system works well until or unless a conflict between the
HCP’s interests and those of the patient results in actions
that harm the patient. Then it is assumed that there has
been a breach of that respected patient-HCP trust.
Many modern situations exist in which the personal
interest of the HCP may not be aligned with that of the
patient. Ethical choices must be made by the HCP in these
situations. Examples include:
● A physician is awakened and gets out of bed in the middle
of the night to assess a patient with chest pain.
● A procedure is done or an antibiotic is given with
marginal indication by the HCP to satisfy the patient’s
wishes rather than the HCP providing a long or detailed
explanation of why the action need not be taken.
● Procedures produce income for HCPs and provide expe-
rience and prestige that are valuable for the HCP in ways
beyond those only for the individual patient’s direct
benefit.
● Medical scientists have a deep interest in developing new
methods or therapies requiring testing in humans despite
the initial imperfection of the agents being tested.
● HCPs continue to devote precious time to help patients
make important behavioral changes (smoking and sub-
stance abuse cessation, dietary counseling, and so on),
despite a lack of reimbursement or support from health
care delivery systems and payers.
● An HCP advocates for a product or procedure because of
his or her role as an adviser or consultant to a company
profiting from the product or procedure while trying to
differentiate this role from that of an impartial physician
or other HCP educator.
● The HCPs are chosen for their opinions to serve as paid
experts in legal actions, de facto taking “sides” in cases
related to patient care or product liability issues.
● A physician prescribes a new statin drug for secondary
prevention because he or she heard about it at a recent
meeting hosted by a drug representative, although this
drug is less proven to prevent subsequent events than
older medications.
Specific high-profile cases in recent years have brought
great attention to the issues of conflict of interest among
those dealing with patients and with subjects of clinical
trials (2,3). There has been sensationalism in the press
addressing some of those cases. In many instances, the
important issue centers around the lack of disclosure to all
concerned of a potential conflict of interest in the HCP’s
relationship with the patient. Although these cases are rare,
they are very important in our profession.
We must ask ourselves, as members of responsible pro-
fessional organizations, “what are the issues in modern
cardiovascular care that create real or potential problems of
conflict of interest for our members and for the organiza-
tions themselves?” We believe the first steps toward provid-
ing advice and direction for HCPs are to identify such
situations and to bring them to an open discussion. We
recognize that publication of some of the specific issues
addressed in this conference may have the effect of increas-
ing the anxiety of the general public and of the media
regarding the extent to which some of the negative situa-
tions occur. However, we believe the initial step on the path
to setting standards for uniform and optimal behavior for
HCPs and the protection of patients is to discuss fully those
areas in which we see cause for concern.
The ACCF and the AHA decided to convene this
conference in order to highlight the potential conflict of
interest in major defined areas and to offer comments about
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their management and resolution. We believe it is our
responsibility to examine ourselves carefully because the
nature of our work and developments in our own specialty of
cardiovascular disease allow us to understand the complex-
ities of many of these issues in 2004 perhaps as well as, or
better than, others.
This conference, which was held in Bethesda, Maryland,
was different from the prior ACCF conferences with “Ethics”
in their titles (4,5). With this conference, we have taken a fresh
approach since many of the issues to be addressed are “new” in
light of the social, economic, and political environment in
which we now find ourselves. The participants in the confer-
ence were widely experienced and brought both “real-world”
and varied perspectives to these issues. They were actively
involved in many areas of cardiovascular subspecialty practice,
teaching, and research. Some of the cardiovascular specialist
participants were employees of industry whose perspectives
were seen as important to the discussions. Nevertheless, they
were invited as colleagues and not as representatives of industry
(nor was their participation sponsored by their companies).
Participants did not uniformly agree on every point, but they
were able to reach consensus on the issues as expressed in the
following Task Force reports.
The Co-Chairs initially did not request a disclosure from
attendees regarding their individual relationships with in-
dustry as none of the groups addressed or discussed specific
companies or products. During the conference and after-
ward, it was appreciated that having a relationship with
industry might be seen as a factor informing or affecting
one’s opinion about the general issues discussed and the
recommendations made. For this reason, we subsequently
asked all participants to disclose such relationships; this
disclosure is published as Appendix 1 to these conference
reports so those reading the reports may be aware of these
relationships with industries.
We believe these reports will be useful for many constit-
uencies. However, the ongoing discussions of the topics
covered here are truly the responsibility of the cardiovascular
HCPs we represent. A responsible profession must police
itself. We hope that this particular function is assisted by
this conference. The decision regarding whether to adopt
the recommendations from this conference as official policy
of the organizations will be the responsibility of the lead-
ership of the ACCF and the AHA.
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